Citizens initiated coverage of Stereotaxis (STXS) with an Outperform rating and $4 price target Stereotaxis develops robotic platforms for use in endovascular surgeries, the analyst tells investors in a research note. The firm views the company as a “unique micro-cap MedTech name worth owning” due to its key product developments set to be tailwinds for system adoption and improved procedural utilization through 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STXS: